Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
96 results about "SERT Proteins" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
SERT is a type of monoamine transporter protein that transports serotonin from the synaptic cleft to the presynaptic neuron. This transport of serotonin by the SERT protein terminates the action of serotonin and recycles it in a sodium-dependent manner.
Methods and compositions for predicting compliance with an antidepressant treatment regimen
InactiveUS20050165115A1Reduce complianceImprove complianceBiocideOrganic active ingredientsGenotype determinationSerotonin transport
Methods and compositions are provided for predicting whether a subject will comply with an antidepressant treatment regimen. In practicing the subject methods, a subject's serotonin transporter gene-linked polymorphic region (5HTTLPR) is genotyped. Based on the identified genotype, a particular antidepressant treatment regimen suitable for the patient is determined. Also provided are kits for practicing the subject methods.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Tetrahydroisoquinoline compounds
Certain tetrahydroisoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.
Owner:JANSSEN PHARMA NV
Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
ActiveUS9708322B2High activityPromote disseminationOrganic active ingredientsOrganic chemistryQuinoxalineDisease
The invention relates to substituted heterocycle fused gamma-carbolines of the Formula Q as described herein, in free base or pharmaceutically acceptable salt form, and / or pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor pathway, the serotonin transporter (SERT) pathway and / or the dopamine D2 receptor pathway signaling systems.
![Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity](https://images-eureka.patsnap.com/patent_img/98a75e2d-75e1-48ce-aec0-985d9e07e9a0/US09708322-20170718-C00001.png "Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity")
![Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity](https://images-eureka.patsnap.com/patent_img/98a75e2d-75e1-48ce-aec0-985d9e07e9a0/US09708322-20170718-C00002.png "Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity")
![Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity](https://images-eureka.patsnap.com/patent_img/98a75e2d-75e1-48ce-aec0-985d9e07e9a0/US09708322-20170718-C00003.png "Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity")
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
ActiveUS9745300B2Strong therapeutic activitySide effect can be reduced and minimizedOrganic active ingredientsIsotope introduction to heterocyclic compoundsDisease5-HT3 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D2 receptor signaling systems.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
ActiveUS20170183350A1To promote metabolismImproves in vitro hepatic microsome stabilityOrganic active ingredientsNervous disorderDisease5-HT3 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H3 receptor and / or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and / or serotonin-mediated diseases.
Owner:JANSSEN PHARMA NV
Organic compounds
ActiveUS10077267B2Similar biological activityTo promote metabolismOrganic active ingredientsIsotope introduction to heterocyclic compoundsDisease5-HT4 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Serotonin transporter gene and treament of alcoholism
ActiveUS20110112159A1Physical improvementImproving psychological sequelaOrganic active ingredientsBiocideDiseaseAlcoholisms
The gene responsible for encoding SERT has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs 1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on variations in the polymorphisms of the SERT gene as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
Certain diaryl-substituted tetrahydroisoquinoline compounds are histamine H3 receptor and / or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and / or serotonin-mediated diseases.
Owner:JANSSEN PHARMA NV
Methods for managing care of patients predisposed to progressive mitral valve diseases
InactiveUS20170058349A1Organic active ingredientsPeptide/protein ingredientsSerotonin transporterGenotyping
The present invention relates to methods for treating or preventing a mitral valve disease in a subject in need thereof, comprising administering to the subject an effective amount of a therapeutic agent. The therapeutic agent is capable of suppressing serotonin receptor signaling. The methods may be combined with a mitral valve surgery, serotonin transporter polymorphism genotyping, MV disease diagnosis, and / or an adjunct assay. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Serotonin transporter gene and treatment of alcoholism
InactiveUS20120115149A1Physical improvementImproving psychological sequelaOrganic active ingredientsMicrobiological testing/measurementAlcoholismsNucleotide
The gene (SLC6A4) responsible for encoding the serotonin transporter (SERT) has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on diagnosing variations in the polymorphisms of the SERT gene and expression and activity of the SERT gene, as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders, for monitoring treatment and / or abuse (addictive behavior), and for determining which treatment should be used.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and therapeutically acceptable salts thereof are provided.
Owner:H LUNDBECK AS +1
Genetic and pharmacological regulation of antidepressant-sensitive biogenic amine transporters through PKG/p38 map kinase
The invention relates to the observation that the p38 mitogen-activated protein kinase pathway is an important regulator of biogenic amine transporter (BAT) function. By using modulator of p38 MAPK, one can alter BAT function in a specific manner. This recognition of the pathway and its interaction with the serotonin transporter (SERT) and the norepinephrine transporter (NET), along with the PPA, PKG and PDE pathways, also provides the opportunity to identify polymorphisms that will impact the efficacy of drugs that act though on these enzymes or their pathways.
Owner:VANDERBILT UNIV
Organic compounds
ActiveUS20170037048A1Avoid side effectsStrong therapeutic activityOrganic active ingredientsIsotope introduction to heterocyclic compoundsDisease5-HT4 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
A3 adenosine receptors as targets for the modulation of central serotonergic signaling
InactiveUS20090088403A1Reducing SERT activityEnhance SERT activityBiocideCarbohydrate active ingredientsSerotonin transporterIn vivo
The present invention relates to the use of adenosine type 3 receptor (A3R) modulators to modulate serotonin transporter (SERT) function in vivo. In particular, antagonists of A3R can be used to inhibit A3R-dependent upregulation of SERT, for example, as antidepressants.
Owner:VANDERBILT UNIV
Organic compounds
ActiveUS10688097B2Inhibit the serotonin re-uptake transporterModulate dopaminergic protein phosphorylationOrganic active ingredientsNervous disorderDiseaseSerotonin transporter
Owner:INTRA CELLULAR THERAPIES INC
Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types
ActiveUS9084825B2Decrease in levelAvoid side effectsOrganic active ingredientsNervous disorderADAMTS ProteinsImaging agent
The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is α-synuclein or the mRNA encoding α-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
Owner:NLIFE THERAPEUTICS
Genetic screening for predicting antidepressant drug response based on the monoamine transporter gene polymorphism combination
The present invention discloses is a method of selecting a drug based on personal genetic information when prescribing an antidepressant for a depressed patient. According to the invention, either a noradrenaline reuptake inhibitor (NRI) antidepressant or a selective serotonin reuptake inhibitor (SSRI) antidepressant can be selected based on the combination of monoamine transporter gene polymorphisms, that is, NET G1287A polymorphism in a norepinephrine transporter (NET) gene, serotonin transporter gene (5-HTT) promoter polymorphism and 5-HTT gene intron 2 polymorphism. Also, based on the norepinephrine transporter gene NET G1287A polymorphism alone, the noradrenaline reuptake inhibitor (NRI) antidepressant can be selected.
Owner:RES & BUSINESS FOUND SUNGKYUNKWAN UNIV
Tropane derivatives useable in particular for in vivo detection of dopamine transporters
The present invention relates to tropane derivatives having particular use for the in vivo detection of dopamine transporters.These derivatives meet the formulain which R1 is I or Sn (R3)3, R2 is for example the methyl group, and X and Y are various substituents.The derivatives with X=CH3 and Y=H show strong specificity for the dopamine transporter compared with the serotonin transporter (74% inhibition when the transporter is previously saturated with GBR 12909).
Owner:CIS BIO INT
Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
ActiveUS20140120158A1Avoid side effectsDecrease in levelOrganic active ingredientsNervous disorderDiseaseImaging agent
The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is α-synuclein or the mRNA encoding α-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
Owner:NLIFE THERAPEUTICS
Gene polymorphism useful for assistance/therapy for smoking cessation
InactiveUS20100003681A1Microbiological testing/measurementDisease diagnosisSerotonin transporterΒ2 subunit
Disclosed is a method for determination of a smoking trend in a subject which is useful for the assistance or therapy for smoking cessation, which comprises the steps of detecting one or more polymorphisms occurring on one or more genes selected from the genes (1) to (3) or a genome or in the neighborhood of the genes or the genome and determining the smoking trend based on the results of the detection: (1) nicotinic acetylcholine receptor β2 subunit (CHRNB2) gene; (2) serotonin transporter (SLC6A4(5HTT)) gene; and (3) nicotinic acetylcholine receptor α4 subunit (CHRNA4) gene.
Owner:OSAKA UNIV +1
Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Serotonin transporter gene and treatment of alcoholism
ActiveUS8697361B2Long durationHigher paroxetine binding (density of SERT)Organic active ingredientsBiocideAlcoholismsNucleotide
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM
InactiveUS20100112706A1Guaranteed reliabilityGuarantee stabilityParticle separator tubesComponent separationImaging agentSerotonin transport
An analytical technique for determining the structures of serotonin transporter (SERT) imaging agent [123I] ADAM and its precursor, SnADAM by using a high-performance liquid chromatography tandem mass spectrometer (LC-MS / MS) is provided. An analytical technique for determining the purity of SnADAM by using a high-performance liquid chromatograph (HPLC) is also provided.
![METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM](https://images-eureka.patsnap.com/patent_img/61107c5b-ba0a-415c-9754-16ba2eb265da/US20100112706A1-20100506-D00000.png "METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM")
![METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM](https://images-eureka.patsnap.com/patent_img/61107c5b-ba0a-415c-9754-16ba2eb265da/US20100112706A1-20100506-D00001.png "METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM")
![METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM](https://images-eureka.patsnap.com/patent_img/61107c5b-ba0a-415c-9754-16ba2eb265da/US20100112706A1-20100506-D00002.png "METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM")
Owner:INST NUCLEAR ENERGY RES ROCAEC
Calamus amide compound as well as preparation method and application of calamus amide compound
The invention provides a calamus amide compound as well as a preparation method and application of the calamus amide compound. The compound is (E)-methyl- 4-[3-(4-hydroxy-3-methoxyphenyl)acrylamido]butanoate or a (Z)-methyl- 4-[3-(4-hydroxy-3-methoxyphenyl)acrylamido]butanoate enol isomer, is separated and purified from roots and stems of acorus tatarinowii serving as an araceae acorus plant, has the effect of promoting the activity of a 5-serotonin transporter (SERT), can be used as a drug for treating depressive disorder, anxiety disorder, schizophrenia, obsession, neurodegenerative diseases, drug addiction or digestive system dysfunction and other diseases, and has an important drug development value.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
InactiveUS20070129419A1Reduce riskKeep it workingBiocideNervous disorderSerotonin transporterANXIETY COMPLEX
The present invention relates to cis-derivatives of formula wherein R1, R2, and R3 are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors). By virtue of their efficacy as SERT inhibitors, the compounds of the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and / or in the treatment of anxiety.
Owner:F HOFFMANN LA ROCHE & CO AG
Boat tropanes
InactiveUS7105678B2Useful in therapyRadioactive preparation carriersRadiation therapyRheniumEnantiomer
Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.
Owner:ORGANIX +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com